Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
”For years, PTEN loss told us which patients would do worse.
Now it may help us identify who can do better.
FDA approves capivasertib + abiraterone + prednisone for PTEN-deficient metastatic hormone-sensitive prostate cancer.
What have we learned?
- We learned that not all prostate cancers are biologically the same.
- We learned that PTEN loss defines a distinct and more aggressive disease subtype.
- And now we learn that this biology can be targeted.
In CAPItello-281, capivasertib improved radiographic PFS by approximately 7.5 months and reduced the risk of progression or death by 19%.
PTEN has moved from being a prognostic biomarker to a therapeutic target. That is how precision oncology changes practice.”
Other Articles Featuring Ahmet Dirican On OncoDaily.
